Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study
Identifieur interne : 001938 ( Main/Curation ); précédent : 001937; suivant : 001939Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study
Auteurs : Tanya Simuni [États-Unis] ; Emily Borushko [États-Unis] ; Michael J. Avram [États-Unis] ; Scott Miskevics [États-Unis] ; Audrey Martel [États-Unis] ; C. Zadikoff [États-Unis] ; Aleksandar Videnovic [États-Unis] ; Frances M. Weaver [États-Unis] ; Karen Williams [États-Unis] ; D. James Surmeier [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-12-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adult, Aged, Calcium Channel Blockers (administration & dosage), Calcium Channel Blockers (adverse effects), Calcium Channel Blockers (therapeutic use), Calcium antagonist, Clinical trial, Humans, Isradipine, Isradipine (administration & dosage), Isradipine (adverse effects), Isradipine (therapeutic use), Middle Aged, Nervous system diseases, Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Pilot Projects, Treatment Outcome, clinical trial, dihydropyridine calcium channel blockers.
- MESH :
- chemical , administration & dosage : Calcium Channel Blockers, Isradipine.
- chemical , adverse effects : Calcium Channel Blockers, Isradipine.
- chemical , therapeutic use : Calcium Channel Blockers, Isradipine.
- drug therapy : Parkinson Disease.
- Adult, Aged, Humans, Middle Aged, Pilot Projects, Treatment Outcome.
Abstract
Recent data suggests that isradipine, a dihydropyridine calcium channel blocker, is neuroprotective in preclinical models of parkinsonism. Isradipine has not been systematically studied in patients with Parkinson's disease (PD). The aim of this study was to evaluate safety and tolerability of isradipine controlled release (CR) in patients with early PD. Qualified subjects (n = 31) received isradipine CR, titrated from 5 to 20 mg daily dose over 8 weeks as tolerated. Eighty‐one percent of subjects completed the study. Tolerability of isradipine CR was dose dependent: 94% for 5 mg dose; 87% for 10 mg; 68% for 15 mg; and 52% for 20 mg. Isradipine had no significant effect on blood pressure or PD motor disability. The two most common reasons for dose reduction were leg edema (7) and dizziness (3). There was no difference in isradipine tolerability between subjects with and without dopaminergic treatment, or with and without hypertension. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23308
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000D77
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :000D77
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000617
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001574
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001574
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001545
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002E43
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :002E43
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002E43
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :001D74
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000758
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :002560
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000776
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :002363
Links to Exploration step
ISTEX:9AE1202002DDA6F5C7F465D199F30A35B6F16867Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study</title>
<author><name sortKey="Simuni, Tanya" sort="Simuni, Tanya" uniqKey="Simuni T" first="Tanya" last="Simuni">Tanya Simuni</name>
</author>
<author><name sortKey="Borushko, Emily" sort="Borushko, Emily" uniqKey="Borushko E" first="Emily" last="Borushko">Emily Borushko</name>
</author>
<author><name sortKey="Avram, Michael J" sort="Avram, Michael J" uniqKey="Avram M" first="Michael J." last="Avram">Michael J. Avram</name>
</author>
<author><name sortKey="Miskevics, Scott" sort="Miskevics, Scott" uniqKey="Miskevics S" first="Scott" last="Miskevics">Scott Miskevics</name>
</author>
<author><name sortKey="Martel, Audrey" sort="Martel, Audrey" uniqKey="Martel A" first="Audrey" last="Martel">Audrey Martel</name>
</author>
<author><name sortKey="Zadikoff, C" sort="Zadikoff, C" uniqKey="Zadikoff C" first="C." last="Zadikoff">C. Zadikoff</name>
</author>
<author><name sortKey="Videnovic, Aleksandar" sort="Videnovic, Aleksandar" uniqKey="Videnovic A" first="Aleksandar" last="Videnovic">Aleksandar Videnovic</name>
</author>
<author><name sortKey="Weaver, Frances M" sort="Weaver, Frances M" uniqKey="Weaver F" first="Frances M." last="Weaver">Frances M. Weaver</name>
</author>
<author><name sortKey="Williams, Karen" sort="Williams, Karen" uniqKey="Williams K" first="Karen" last="Williams">Karen Williams</name>
</author>
<author><name sortKey="Surmeier, D James" sort="Surmeier, D James" uniqKey="Surmeier D" first="D. James" last="Surmeier">D. James Surmeier</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:9AE1202002DDA6F5C7F465D199F30A35B6F16867</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.23308</idno>
<idno type="url">https://api.istex.fr/document/9AE1202002DDA6F5C7F465D199F30A35B6F16867/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000D77</idno>
<idno type="wicri:Area/Istex/Curation">000D77</idno>
<idno type="wicri:Area/Istex/Checkpoint">000617</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Simuni T:tolerability:of:isradipine</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:20818667</idno>
<idno type="wicri:Area/PubMed/Corpus">001574</idno>
<idno type="wicri:Area/PubMed/Curation">001574</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001545</idno>
<idno type="wicri:Area/Ncbi/Merge">002E43</idno>
<idno type="wicri:Area/Ncbi/Curation">002E43</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002E43</idno>
<idno type="wicri:Area/Main/Merge">001D74</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:11-0065145</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000758</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002560</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000776</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Simuni T:tolerability:of:isradipine</idno>
<idno type="wicri:Area/Main/Merge">002363</idno>
<idno type="wicri:Area/Main/Curation">001938</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study</title>
<author><name sortKey="Simuni, Tanya" sort="Simuni, Tanya" uniqKey="Simuni T" first="Tanya" last="Simuni">Tanya Simuni</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Borushko, Emily" sort="Borushko, Emily" uniqKey="Borushko E" first="Emily" last="Borushko">Emily Borushko</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Avram, Michael J" sort="Avram, Michael J" uniqKey="Avram M" first="Michael J." last="Avram">Michael J. Avram</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Miskevics, Scott" sort="Miskevics, Scott" uniqKey="Miskevics S" first="Scott" last="Miskevics">Scott Miskevics</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Hines VA Hospital, Hines, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Martel, Audrey" sort="Martel, Audrey" uniqKey="Martel A" first="Audrey" last="Martel">Audrey Martel</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zadikoff, C" sort="Zadikoff, C" uniqKey="Zadikoff C" first="C." last="Zadikoff">C. Zadikoff</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Videnovic, Aleksandar" sort="Videnovic, Aleksandar" uniqKey="Videnovic A" first="Aleksandar" last="Videnovic">Aleksandar Videnovic</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Weaver, Frances M" sort="Weaver, Frances M" uniqKey="Weaver F" first="Frances M." last="Weaver">Frances M. Weaver</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Hines VA Hospital, Hines, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Williams, Karen" sort="Williams, Karen" uniqKey="Williams K" first="Karen" last="Williams">Karen Williams</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Surmeier, D James" sort="Surmeier, D James" uniqKey="Surmeier D" first="D. James" last="Surmeier">D. James Surmeier</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Physiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-12-15">2010-12-15</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">16</biblScope>
<biblScope unit="page" from="2863">2863</biblScope>
<biblScope unit="page" to="2866">2866</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">9AE1202002DDA6F5C7F465D199F30A35B6F16867</idno>
<idno type="DOI">10.1002/mds.23308</idno>
<idno type="ArticleID">MDS23308</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Calcium Channel Blockers (administration & dosage)</term>
<term>Calcium Channel Blockers (adverse effects)</term>
<term>Calcium Channel Blockers (therapeutic use)</term>
<term>Calcium antagonist</term>
<term>Clinical trial</term>
<term>Humans</term>
<term>Isradipine</term>
<term>Isradipine (administration & dosage)</term>
<term>Isradipine (adverse effects)</term>
<term>Isradipine (therapeutic use)</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Pilot Projects</term>
<term>Treatment Outcome</term>
<term>clinical trial</term>
<term>dihydropyridine calcium channel blockers</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Calcium Channel Blockers</term>
<term>Isradipine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Calcium Channel Blockers</term>
<term>Isradipine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Calcium Channel Blockers</term>
<term>Isradipine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antagoniste calcium</term>
<term>Essai clinique</term>
<term>Isradipine</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Recent data suggests that isradipine, a dihydropyridine calcium channel blocker, is neuroprotective in preclinical models of parkinsonism. Isradipine has not been systematically studied in patients with Parkinson's disease (PD). The aim of this study was to evaluate safety and tolerability of isradipine controlled release (CR) in patients with early PD. Qualified subjects (n = 31) received isradipine CR, titrated from 5 to 20 mg daily dose over 8 weeks as tolerated. Eighty‐one percent of subjects completed the study. Tolerability of isradipine CR was dose dependent: 94% for 5 mg dose; 87% for 10 mg; 68% for 15 mg; and 52% for 20 mg. Isradipine had no significant effect on blood pressure or PD motor disability. The two most common reasons for dose reduction were leg edema (7) and dizziness (3). There was no difference in isradipine tolerability between subjects with and without dopaminergic treatment, or with and without hypertension. © 2010 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2010:Simuni T:tolerability:of:isradipine"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Tolerability of Isradipine in Early Parkinson's Disease: A Pilot Dose Escalation Study</title>
<author><name sortKey="Simuni, Tanya" sort="Simuni, Tanya" uniqKey="Simuni T" first="Tanya" last="Simuni">Tanya Simuni</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Northwestern University, Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Borushko, Emily" sort="Borushko, Emily" uniqKey="Borushko E" first="Emily" last="Borushko">Emily Borushko</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Northwestern University, Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Avram, Michael J" sort="Avram, Michael J" uniqKey="Avram M" first="Michael J." last="Avram">Michael J. Avram</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Pharmacology, Northwestern University, Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Miskevics, Scott" sort="Miskevics, Scott" uniqKey="Miskevics S" first="Scott" last="Miskevics">Scott Miskevics</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Hines VA Hospital</s1>
<s2>Hines, Illinois</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Martel, Audrey" sort="Martel, Audrey" uniqKey="Martel A" first="Audrey" last="Martel">Audrey Martel</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Northwestern University, Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zadikoff, C" sort="Zadikoff, C" uniqKey="Zadikoff C" first="C." last="Zadikoff">C. Zadikoff</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Northwestern University, Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Videnovic, Aleksandar" sort="Videnovic, Aleksandar" uniqKey="Videnovic A" first="Aleksandar" last="Videnovic">Aleksandar Videnovic</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Northwestern University, Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Weaver, Frances M" sort="Weaver, Frances M" uniqKey="Weaver F" first="Frances M." last="Weaver">Frances M. Weaver</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Hines VA Hospital</s1>
<s2>Hines, Illinois</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Williams, Karen" sort="Williams, Karen" uniqKey="Williams K" first="Karen" last="Williams">Karen Williams</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Northwestern University, Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Surmeier, D James" sort="Surmeier, D James" uniqKey="Surmeier D" first="D. James" last="Surmeier">D. James Surmeier</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Physiology, Northwestern University, Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0065145</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 11-0065145 INIST</idno>
<idno type="RBID">Pascal:11-0065145</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000758</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002560</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000776</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Simuni T:tolerability:of:isradipine</idno>
<idno type="wicri:Area/Main/Merge">002363</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Tolerability of Isradipine in Early Parkinson's Disease: A Pilot Dose Escalation Study</title>
<author><name sortKey="Simuni, Tanya" sort="Simuni, Tanya" uniqKey="Simuni T" first="Tanya" last="Simuni">Tanya Simuni</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Northwestern University, Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Borushko, Emily" sort="Borushko, Emily" uniqKey="Borushko E" first="Emily" last="Borushko">Emily Borushko</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Northwestern University, Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Avram, Michael J" sort="Avram, Michael J" uniqKey="Avram M" first="Michael J." last="Avram">Michael J. Avram</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Pharmacology, Northwestern University, Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Miskevics, Scott" sort="Miskevics, Scott" uniqKey="Miskevics S" first="Scott" last="Miskevics">Scott Miskevics</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Hines VA Hospital</s1>
<s2>Hines, Illinois</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Martel, Audrey" sort="Martel, Audrey" uniqKey="Martel A" first="Audrey" last="Martel">Audrey Martel</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Northwestern University, Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zadikoff, C" sort="Zadikoff, C" uniqKey="Zadikoff C" first="C." last="Zadikoff">C. Zadikoff</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Northwestern University, Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Videnovic, Aleksandar" sort="Videnovic, Aleksandar" uniqKey="Videnovic A" first="Aleksandar" last="Videnovic">Aleksandar Videnovic</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Northwestern University, Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Weaver, Frances M" sort="Weaver, Frances M" uniqKey="Weaver F" first="Frances M." last="Weaver">Frances M. Weaver</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Hines VA Hospital</s1>
<s2>Hines, Illinois</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Williams, Karen" sort="Williams, Karen" uniqKey="Williams K" first="Karen" last="Williams">Karen Williams</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Northwestern University, Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Surmeier, D James" sort="Surmeier, D James" uniqKey="Surmeier D" first="D. James" last="Surmeier">D. James Surmeier</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Physiology, Northwestern University, Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Calcium antagonist</term>
<term>Clinical trial</term>
<term>Isradipine</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Isradipine</term>
<term>Essai clinique</term>
<term>Antagoniste calcium</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Recent data suggests that isradipine, a dihydropyridine calcium channel blocker, is neuroprotective in preclinical models of parkinsonism. Isradipine has not been systematically studied in patients with Parkinson's disease (PD). The aim of this study was to evaluate safety and tolerability of isradipine controlled release (CR) in patients with early PD. Qualified subjects (n = 31) received isradipine CR, titrated from 5 to 20 mg daily dose over 8 weeks as tolerated. Eighty-one percent of subjects completed the study. Tolerability of isradipine CR was dose dependent: 94% for 5 mg dose; 87% for 10 mg; 68% for 15 mg; and 52% for 20 mg. Isradipine had no significant effect on blood pressure or PD motor disability. The two most common reasons for dose reduction were leg edema (7) and dizziness (3). There was no difference in isradipine tolerability between subjects with and without dopaminergic treatment, or with and without hypertension.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study</title>
<author><name sortKey="Simuni, Tanya" sort="Simuni, Tanya" uniqKey="Simuni T" first="Tanya" last="Simuni">Tanya Simuni</name>
</author>
<author><name sortKey="Borushko, Emily" sort="Borushko, Emily" uniqKey="Borushko E" first="Emily" last="Borushko">Emily Borushko</name>
</author>
<author><name sortKey="Avram, Michael J" sort="Avram, Michael J" uniqKey="Avram M" first="Michael J." last="Avram">Michael J. Avram</name>
</author>
<author><name sortKey="Miskevics, Scott" sort="Miskevics, Scott" uniqKey="Miskevics S" first="Scott" last="Miskevics">Scott Miskevics</name>
</author>
<author><name sortKey="Martel, Audrey" sort="Martel, Audrey" uniqKey="Martel A" first="Audrey" last="Martel">Audrey Martel</name>
</author>
<author><name sortKey="Zadikoff, C" sort="Zadikoff, C" uniqKey="Zadikoff C" first="C." last="Zadikoff">C. Zadikoff</name>
</author>
<author><name sortKey="Videnovic, Aleksandar" sort="Videnovic, Aleksandar" uniqKey="Videnovic A" first="Aleksandar" last="Videnovic">Aleksandar Videnovic</name>
</author>
<author><name sortKey="Weaver, Frances M" sort="Weaver, Frances M" uniqKey="Weaver F" first="Frances M." last="Weaver">Frances M. Weaver</name>
</author>
<author><name sortKey="Williams, Karen" sort="Williams, Karen" uniqKey="Williams K" first="Karen" last="Williams">Karen Williams</name>
</author>
<author><name sortKey="Surmeier, D James" sort="Surmeier, D James" uniqKey="Surmeier D" first="D. James" last="Surmeier">D. James Surmeier</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:9AE1202002DDA6F5C7F465D199F30A35B6F16867</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.23308</idno>
<idno type="url">https://api.istex.fr/document/9AE1202002DDA6F5C7F465D199F30A35B6F16867/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000D77</idno>
<idno type="wicri:Area/Istex/Curation">000D77</idno>
<idno type="wicri:Area/Istex/Checkpoint">000617</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Simuni T:tolerability:of:isradipine</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:20818667</idno>
<idno type="wicri:Area/PubMed/Corpus">001574</idno>
<idno type="wicri:Area/PubMed/Curation">001574</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001545</idno>
<idno type="wicri:Area/Ncbi/Merge">002E43</idno>
<idno type="wicri:Area/Ncbi/Curation">002E43</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002E43</idno>
<idno type="wicri:Area/Main/Merge">001D74</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study</title>
<author><name sortKey="Simuni, Tanya" sort="Simuni, Tanya" uniqKey="Simuni T" first="Tanya" last="Simuni">Tanya Simuni</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Borushko, Emily" sort="Borushko, Emily" uniqKey="Borushko E" first="Emily" last="Borushko">Emily Borushko</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Avram, Michael J" sort="Avram, Michael J" uniqKey="Avram M" first="Michael J." last="Avram">Michael J. Avram</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Miskevics, Scott" sort="Miskevics, Scott" uniqKey="Miskevics S" first="Scott" last="Miskevics">Scott Miskevics</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Hines VA Hospital, Hines, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Martel, Audrey" sort="Martel, Audrey" uniqKey="Martel A" first="Audrey" last="Martel">Audrey Martel</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zadikoff, C" sort="Zadikoff, C" uniqKey="Zadikoff C" first="C." last="Zadikoff">C. Zadikoff</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Videnovic, Aleksandar" sort="Videnovic, Aleksandar" uniqKey="Videnovic A" first="Aleksandar" last="Videnovic">Aleksandar Videnovic</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Weaver, Frances M" sort="Weaver, Frances M" uniqKey="Weaver F" first="Frances M." last="Weaver">Frances M. Weaver</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Hines VA Hospital, Hines, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Williams, Karen" sort="Williams, Karen" uniqKey="Williams K" first="Karen" last="Williams">Karen Williams</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Surmeier, D James" sort="Surmeier, D James" uniqKey="Surmeier D" first="D. James" last="Surmeier">D. James Surmeier</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Physiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-12-15">2010-12-15</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">16</biblScope>
<biblScope unit="page" from="2863">2863</biblScope>
<biblScope unit="page" to="2866">2866</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">9AE1202002DDA6F5C7F465D199F30A35B6F16867</idno>
<idno type="DOI">10.1002/mds.23308</idno>
<idno type="ArticleID">MDS23308</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Calcium Channel Blockers (administration & dosage)</term>
<term>Calcium Channel Blockers (adverse effects)</term>
<term>Calcium Channel Blockers (therapeutic use)</term>
<term>Humans</term>
<term>Isradipine (administration & dosage)</term>
<term>Isradipine (adverse effects)</term>
<term>Isradipine (therapeutic use)</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson's disease</term>
<term>Pilot Projects</term>
<term>Treatment Outcome</term>
<term>clinical trial</term>
<term>dihydropyridine calcium channel blockers</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Calcium Channel Blockers</term>
<term>Isradipine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Calcium Channel Blockers</term>
<term>Isradipine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Calcium Channel Blockers</term>
<term>Isradipine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Recent data suggests that isradipine, a dihydropyridine calcium channel blocker, is neuroprotective in preclinical models of parkinsonism. Isradipine has not been systematically studied in patients with Parkinson's disease (PD). The aim of this study was to evaluate safety and tolerability of isradipine controlled release (CR) in patients with early PD. Qualified subjects (n = 31) received isradipine CR, titrated from 5 to 20 mg daily dose over 8 weeks as tolerated. Eighty‐one percent of subjects completed the study. Tolerability of isradipine CR was dose dependent: 94% for 5 mg dose; 87% for 10 mg; 68% for 15 mg; and 52% for 20 mg. Isradipine had no significant effect on blood pressure or PD motor disability. The two most common reasons for dose reduction were leg edema (7) and dizziness (3). There was no difference in isradipine tolerability between subjects with and without dopaminergic treatment, or with and without hypertension. © 2010 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001938 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001938 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:9AE1202002DDA6F5C7F465D199F30A35B6F16867 |texte= Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |